Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Distant metastasis is the primary barrier for the successful treatment of patients with colorectal cancer, and thus, searching for new therapeutic targets by further exploring the molecular mechanisms of colorectal cancer metastasis is important. In this study, we investigated the biological and clinical significance of
RASSF6
in colorectal cancer as well as the underlying molecular mechanisms. We found that low
RASSF6
expression corresponds to a poor prognosis in colorectal cancer patients, and low
RASSF6
expression is distinctly associated with tumour progression. Our
in vitro
analysis revealed that
RASSF6
suppresses the proliferation and metastasis of DLD1 cells, and
RASSF6
knockdown in HCT116 cells confirmed these observations. Our mechanistic investigation revealed that
RASSF6
inhibits the expression of the classical target genes of Wnt signalling, as demonstrated by the reduced expression of TCF1,
c-Jun
, and c-Myc in
RASSF6
-overexpressing DLD1 stable cell lines. Furthermore, we show that
RASSF6
functions as a negative regulator of the epithelial-mesenchymal transition; the expression levels of the epithelial markers ZO-1 and E-cadherin were increased, while the expression level of the mesenchymal marker Snail was decreased in a
RASSF6
-overexpressing DLD1 cell line. Additionally, rescue assays revealed that the activation of Wnt signalling by LiCl treatment impaired the inhibitory effect of
RASSF6
on the proliferation and metastasis of colorectal cancer cells, which implies that
RASSF6
suppresses the tumorigenicity of colorectal cancer cells at least in part through inhibiting Wnt signalling pathway. Collectively, these findings provide new perspectives for the future study of
RASSF6
as a therapeutic target for colorectal cancer.
...
PMID:RASSF6 downregulation promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal cancer. 2890 10